Topical pravibismane was found to be safe and well-tolerated for all doses tested in subjects with moderate to severely infected, chronic diabetic foot ulcers Pravibismane treatment demonstrated favorable trends towards… Read More
Michael Smith Health Research BC is pleased to open the 2024 Convening & Collaborating (C2) and Reach competitions, with additional funding to address priority health challenges. Through these programs, we… Read More
INM-901 receptor binding studies indicate preferential signaling agonism for CB1/CB2 and impacts the PPAR signaling pathway In Vivo studies demonstrate INM-901 reduces neuroinflammation and improves neuronal function Molecular analysis data… Read More
Company’s listing application approved by Nasdaq VICTORIA, BC – Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (TSX: EPRX); (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology to optimize… Read More
Clairvoyant on target for potential commercialization of psilocybin treatment in 2025 VANCOUVER, BC – Clairvoyant Therapeutics Inc. (www.clairvoyantrx.com), the private clinical-stage pharmaceutical company developing psilocybin treatment for alcohol use disorder (AUD),… Read More
